TABLE 1.
Demographics and clinical data
| Characteristic | Value or identifier for groupa |
||||
|---|---|---|---|---|---|
| GA < 32 wks |
GA ≥ 32 wks |
Total | |||
| PNA < 14 days | PNA ≥14 days | PNA < 14 day | PNA ≥14 days | ||
| Cohort no. | 1 | 2 | 3 | 4 | |
| No. of subjects | 12 | 9 | 8 | 3 | 32 |
| Doseb (mg/kg) | 80 (50–101) | 80 (54–98) | 80 (75–81) | 79 (72–105) | 80 (50–105) |
| GA (wks) | 28 (26–32) | 28 (23–32) | 38 (32–40) | 37 (33–40) | 30 (23–40) |
| PNA (days) | 2 (1–14) | 28 (15–60) | 1 (1–12) | 43 (30–59) | 8 (1–60) |
| PMA (wks) | 29 (27–32) | 33 (25–37) | 39 (32–41) | 43 (37–48) | 32 (25–48) |
| Wt (g) | 1,109 (727–1,580) | 1,397 (473–1,855) | 3,248 (1,480–3,990) | 3,050 (2,300, 3,050) | 1,439 (473–3,990) |
| SCR (mg/dl) | 0.8 (0.6–2.0) | 0.8 (0.4–1.9) | 0.8 (0.3–1.1) | 0.6 (0.3–0.7) | 0.8 (0.3–2.0) |
| % with: | |||||
| Gentamicin use | 33 | 100 | 75 | 33 | 63 |
| Dopamine use | 17 | 11 | 13 | 0 | 13 |
| Epinephrine use | 8 | 0 | 13 | 0 | 6 |
| % Male | 67 | 78 | 38 | 67 | 63 |
a
Data are median (range), unless otherwise indicated.
b
Piperacillin component (piperacillin-tazobactam were given in combination at a fixed ratio of 8:1).